Dimesna

Dimesna combined with anticancer chemotherapeutic agents to reduce nephrotoxicity.

Product Specifications

CAS Number

[16208-51-8]

Product Name Alternative

BNP-7787

UNSPSC

12352100

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Dimesna.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 68 mg/mL (ultrasonic; warming) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=S(CCSSCCS(=O)(O[Na])=O)(O[Na])=O

Molecular Formula

C4H8Na2O6S4

Molecular Weight

326.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Parker AR, et al. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro. Mol Cancer Ther. 2010 Sep;9 (9) :2558-2567.|[2]Hausheer FH, et al.Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol. 2010 Apr;65 (5) :941-951.|[3]Cutler MJ, et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52 (4) :530-542.|[4]Habs MR, et al. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna) . Cancer. 1983 Feb 15;51 (4) :606-609.